LEADER 01700nam  2200457   450 
001 9910707259203321
005 20160613085131.0
035   $a(CKB)5470000002462915
035   $a(OCoLC)951607480
035   $a(OCoLC)995470000002462915
035   $a(EXLCZ)995470000002462915
100   $a20160613d2014      ua             0
101 0 $aeng
135   $aurmn|||||||||
181   $2rdacontent
182   $2rdamedia
183   $2rdacarrier
200 10$aManufacturer safeguards may not prevent copayment coupon use for Part D drugs
210  1$aWashington, DC :$cDepartment of Health and Human Services, Office of Inspector General,$d2014.
215   $a1 online resource (29 pages) $ccolor illustrations
300   $aTitle from title screen (viewed June 13, 2016).
300   $a"September 2014."
300   $a"OEI-05-12-00540."
320   $aIncludes bibliographical references.
517 1 $aManufacturer safeguards may not prevent copayment coupon use for Part D drugs
606   $aMedicare$xClaims administration
606   $aPharmaceutical industry$zUnited States
606   $aNonprescription drug industry$zUnited States
606   $aCopayments (Insurance)$xLaw and legislation$zUnited States
606   $aDrugs$xPrices$zUnited States
615  0$aMedicare$xClaims administration.
615  0$aPharmaceutical industry
615  0$aNonprescription drug industry
615  0$aCopayments (Insurance)$xLaw and legislation
615  0$aDrugs$xPrices
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910707259203321
996   $aManufacturer safeguards may not prevent copayment coupon use for Part D drugs$93281976
997   $aUNINA